34 results about "Bone marrow sample" patented technology

The present invention provides a system and apparatuses / devices capable of automatically performing the processes of cell treatment preparatory to flow cytometry and similar cytological studies in a fully automated and streamlined manner. The system and apparatuses / devices are being adapted for preparation and (pre)processing of cell samples, e.g. blood and / or bone marrow samples.

The present application is directed to the separation of—a solid fraction from a fluid sample particularly a therapeutic cellular fraction from a biological sample such as a bone marrow sample by a porous filter (2) which separates a filtration unit (1) into an upper pre-filtration chamber (3) into which a fluid sample (4) requiring cell separation is introduced and a lower post-filtration chamber (5) into which a fluid (6) capable of transmitting an acoustic standing wave is introduced. An acoustic element (8) is coupled to a substrate (7) which is located within and at the bottom of the lower chamber (5) and which resonates in response to the acoustic generating element (8) and generates a standing wave through the two fluid phases and the filter to agitate the sample (4). Simultaneously, a cyclic process of vacuum draw (9). causes movement of the sample (4) downwards through the filter (2). Vacuum pressure, fluid flow rate and frequency of vibration are controlled from a remote unit housing appropriate pumps and valves.

The invention relates to an automatic bone marrow sample processing device, and an automatic analyzing and radiograph reading method thereof. The device combines automatic staining technology, sample quality automatic detection technology, encrpytion technology, microscopical technology and image processing technology, and can realize the all-around automation of staining, scanning and radiograph reading. The automatic radiograph reading method comprises the steps of firstly, performing low-power lens complete sample scanning and splicing, so as to obtain a low-power lens complete sample panoramic image, then inputting an interested characteristic parameter set, and finally performing high-power lens interested region scanning and splicing, so as to obtain a high-power lens interested region panoramic image set. Compared with the traditional bone marrow sample processing and radiograph reading method, the automatic analyzing and radiograph reading method has the advantages that the problem that the complete marrow sample quality cannot be checked by doctors on the whole is solved, and the radiograph reading speed and accuracy of doctors are improved. The low-power lens panoramic image and the high-power lens panoramic image set obtained can serve as an objective base and experimental data for clinical diagnosis and provide a necessary support for the development of myelopathy diagnostics, and are huge in social benefit.

A method of preparing nucleated peripheral blood or bone marrow cells optimized for at least dual mode imaging. The method including: (a) isolating nucleated cells from a peripheral blood or a bone marrow sample; and (b) resuspending the nucleated cells in the presence of a morphology preserver including at least 1% serum, and recovering a cell fraction thereby preparing the nucleated peripheral blood or bone marrow cells optimized for at least dual mode imaging.

This disclosure describes systems, methods, and apparatus for forming concentrates of platelet-rich plasma or bone marrow cells having user-defined concentrations, concentration ranges, and / or volumes. Whole blood or bone marrow samples can be passed through one or two separation operations in which platelets or bone marrow cells are separated from red blood cells and concentrated in a plasma. During this separation and concentrating, a total number of platelets or bone marrow cells or a concentration of either is determined and then used to ascertain what volumes and concentrations need be mixed in order to produce a platelet-rich plasma concentrate or a bone marrow-rich plasma concentrate having a target concentration and / or volume.

Methods for diagnosing multiple myeloma are disclosed. These methods are based upon the observation that tumor rejection antigen precursors are expressed in multiple myeloma. By assaying bone marrow samples, one can diagnose multiple myeloma, and also monitor the disease's progress. Therapeutic approaches to multiple myeloma are also disclosed.

The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide. Further, the elderly AML patients identified as being likely responsive to the combination treatment with tipinifarb and etoposide have a complete recovery rate comparable to the best therapy available for younger patients.

The present invention relates to the field of cancer therapy. More specifically, the present invention provides methods and compositions useful for augmenting anti-tumor immunity. In one embodiment, a method for treating or preventing post-allogeneic transplant relapse in a subject who has received post-transplant cyclophosphamide treatment comprises the steps of (a) obtaining a bone marrow sample from the subject; (b) expanding the marrow infiltrating lymphocytes (MILs) present in the sample; and (c) administering the MILs to the subject. In a specific embodiment, the method significantly reduces the likelihood of developing GVHD.

A system and apparatuses or devices capable of automatically performing processes of cell treatment preparatory to flow cytometry and similar cytological studies in a fully automated and streamlined manner are provided. The system and apparatuses or devices are adapted for preparation and (pre)processing of cell samples, e.g., blood and / or bone marrow samples.

The invention discloses a hematology bone marrow puncture extracting device. The device comprises an outer tube body and a base, the outer tube body is internally and fixedly connected with an inner tube body, a first piston is slidably connected between the inner surface of the outer tube body and the outer surface of the inner tube body, the top of the first piston is fixedly connected with a pushing tube, the pushing sleeves the inner tube body, the top of the pushing tube extends to the exterior of the outer tube body, the top of the pushing tube is fixedly connected with a first pushing plate, and the hematology bone marrow puncture extracting device relates to the technical field of medical instruments. The hematology bone marrow puncture extracting device has the advantages that theouter tube body and the inner tube body are cooperatively used together with an inner needle head and an outer needle head, the outer tube body is used for storing anaesthetic, the inner tube body isused for storing bone marrow samples, so that the extracted bone marrow does not contain the anaesthetic, the quality of bone marrow is not influenced, a first piston and a second piston can be pushed to slide by the pushing tube and a crossed pushing rod respectively to be used for anaesthetic injection and bone marrow extraction, the pushing tube and the crossed pushing rod do not interfere with each other, and the use is convenient.

The invention relates to an acute myeloid leukemia miRNA and transcription factor model and a construction method and application thereof. The construction method includes: acquiring differential expression miRNA and different expression transcription factors of marrow samples of acute myeloid leukemia patients and a healthy contrast group, constructing a miRNA-transcription factor regulatory network model to obtain core miRNA and core transcription factors, and the like. The constructed miRNA and transcription factor model can be used for construction of diagnosis probes, chips or reagents, equipment and the like to provide intermediate result information or reference information for diagnosis of the acute myeloid leukemia patients. By the acute myeloid leukemia miRNA and transcription factor model, microRNA mediated network regulation contents are enriched, and an action mechanism of a microRNA and transcription factor mediated regulation network in AML (acute myeloid leukemia) is revealed. Research results lay the foundation for development of anti-leukemia medicines or biological products, and high application value is achieved.

Methods for diagnosing multiple myeloma are disclosed. These methods are based upon the observation that tumor rejection antigen precursors are expressed in multiple myeloma. By assaying bone marrow samples, one can diagnose multiple myeloma, and also monitor the disease's progress. Therapeutic approaches of multiple myeloma are also disclosed.

The invention provides methods of using isolated monocyte populations to treat subjects suffering from various ocular vascular disease or ocular degenerative disorders. The present invention also provides novel methods for isolating substantially pure monocyte populations. The methods involve extracting a blood sample or a bone marrow sample from a subject, debulking red blood cells from the sample, and then separating remaining red blood cells and other cell types in the sample from monocytes. Instead of using any selection or labeling agents, the red blood cells and other cell types are separated from monocytes based on their size, granularity or density. The isolated monocytes can be further activated in vitro or ex vivo prior to being administered to a subject. Isolated cell populations containing substantially pure CD14+ / CD33+ monocytes are also provided in the invention.

This disclosure describes systems, methods, and apparatuses for forming concentrates of platelet-rich plasma or bone marrow cells having user-defined concentrations, concentration ranges, and / or volumes. Whole blood or bone marrow samples can be passed through one or two separation operations in which platelets or bone marrow cells are separated from red blood cells and concentrated in a plasma. During this separation and concentrating, a total number of platelets or bone marrow cells or a concentration of either is determined and then used to ascertain what volumes and concentrations need be mixed in order to produce a platelet-rich plasma concentrate or a bone marrow-rich plasma concentrate having a target concentration and / or volume.

The invention provides methods of using isolated monocyte populations to treat subjects suffering from various ocular vascular disease or ocular degenerative disorders. The present invention also provides novel methods for isolating substantially pure monocyte populations. The methods involve extracting a blood sample or a bone marrow sample from a subject, debulking red blood cells from the sample, and then separating remaining red blood cells and other cell types in the sample from monocytes. Instead of using any selection or labeling agents, the red blood cells and other cell types are separated from monocytes based on their size, granularity or density. The isolated monocytes can be further activated in vitro or ex vivo prior to being administered to a subject. Isolated cell populations containing substantially pure CD14+ / CD33+ monocytes are also provided in the invention.

The present invention discloses using SPR technology to detect MM related genomic imbalances in bone marrow samples. An efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of DNA markers used for the identification of MM related genomic imbalances in bone marrow samples is also disclosed.

The invention relates to the technical field of gene detection, in particular to a fluorescence in-situ hybridization probe set for detecting AML1 / ETO genes and application of the fluorescence in-situ hybridization probe set. The probe group is prepared from 2440 nucleotide sequences shown in the specification table 1. According to the invention, in a target region of AML1 and ETO genes, a single-chain fragment which is completely complementary to the target region and has a length of 45bp is directly constructed as a candidate probe, and then each sequence is subjected to batch BLAST comparison, so that high specificity of each hybridized probe sequence is ensured; meanwhile, the targeting of a target area is accurately controlled, the size limitation of the probe is broken through, and the resolution of the probe is improved; in the preparation process, a PCR (Polymerase Chain Reaction) doping method is adopted to ensure that the product contains more fluorophores. The probe group is used for detecting the AML1 / ETO gene rearrangement state, the cost is low, FISH hybridization of a bone marrow sample can be completed within about 30 minutes, the sensitivity is high, the specificity is strong, the hybridization background is clean, and the signal-to-noise ratio is low.

The invention provides a method for leukaemia high-flux medicine screening. The method comprises the following steps of performing separation, extraction, identification and culture on neoplastic hematologic disorder stem cells: performing acquisition on bone marrow samples, performing separation on mononuclear cells, performing separation on leukaemia stem cell groups through an immunomagnetic bead method; and performing subculturing on the cells after separation and purification of magnetic beads; and establishing a medicine library: according to a medicine description and pharmacokinetics,selecting the concentration of medicines, performing mixed culture on the medicines and the neoplastic hematologic disorder stem cells, and analyzing the restraining effect of the medicines on the neoplastic hematologic disorder stem cells. According to the method for leukaemia high-flux medicine screening disclosed by the invention, in accordance with a patient, an appropriate treatment scheme and opinions can be accurately given in an individualizing manner, a valuable treatment opportunity is strived for the recurrent and refractory patient, reagent risk is reduced, the medicine curative effect is increased to the maximum degree, and medicine side effects are reduced to the maximum degree; and besides, pharmaceutical combinations can be performed, in accordance with clinical frequently-used chemotherapeutics combinations, comprehensive marking is performed, and a reference is provided for a doctor in the respect of formulating clinical united medication for the patient.

The invention provides a nucleic acid separator for gene detection in treatment on progressive myodystrophy. The nucleic acid separator comprises core-shell magnetic nano-particles having high dispersity and particle sizes of 30 to 80nm. Through chemical modification, the nucleic acid separator can realize that surfaces of magnetic nano-particles are modified by needed function groups. The nucleic acid separator can realize direct extraction of a genomic DNA from peripheral blood and bone marrow samples, and realize target gene or target nucleic acid detection by a fast reaction system and a magnetic nanotechnology. The invention is suitable for high-flux separation of a gene or a nucleic acid in a clinical stem cell therapy of progressive myodystrophy.

The present invention relates to an arrangement for sinus evacuation and for taking a sample of bone marrow during a bone marrow aspiration procedure as well as a bone marrow biopsy procedure. By applying a longitudinal movement to the needle when the needle is penetrating the bone the penetration force is reduced which lower the risk of penetrating the posterior cortex or the second sinus wall. The arrangement further comprises stopping means that prevents the needle to penetrate deeper than to a predetermined depth. The arrangement further comprises longitudinal movement stopping means that provides for an active break of the longitudinal movement of the needle when the needle has penetrated down to the predetermined depth.

The present invention relates to the field of cancer therapy. More specifically, the present invention provides methods and compositions useful for augmenting anti-tumor immunity. In one embodiment, a method for treating or preventing post-allogeneic transplant relapse in a subject who has received post-transplant cyclophosphamide treatment comprises the steps of (a) obtaining a bone marrow sample from the subject; (b) expanding the marrow infiltrating lymphocytes (MILs) present in the sample; and (c) administering the MILs to the subject. In a specific embodiment, the method significantly reduces the likelihood of developing GVHD.

The invention relates to the field of leukaemia drug resistance and discloses application of an ALC1 inhibitor to preparation of a leukaemia drug resistance reversing agent and application of an ALC1 gene to preparation of a drug-resistant leukaemia diagnosing reagent. The expression of the ALC1 gene in a peripheral blood sample or a bone marrow sample of a patient is detected; and based on a characteristic that the high expression of the gene is related to the increase of the resistance of a cell to chemotherapeutic medicines, sensitive chemotherapeutic agents can be screened. The invention further discloses an application of the ALC1 gene to preparation of the leukaemia drug resistance reversing agent. By inhibiting the expression of the ALC1 gene, the drug resistance of the cell can bereversed, the sensitivity of a leukemia cell to the medicine can be improved, and the cell inhibiting effects and the apoptosis promoting effects of various chemotherapeutic medicines can be improved, so that the ALC1 inhibitor can be applied to the preparation of acute and chronic leukaemia multidrug resistance reversing agents and a new method for treating the drug-resistant leukaemia is provided.

The invention belongs to the technical field of biology, and particularly relates to a human leukemia BCR-ABL fusion mutation one-step detection kit based on digital PCR technology one-step detection. The human leukemia BCR-ABL fusion mutation one-step detection kit comprises: premixed liquid for microdroplet type digital PCR; a BCR-ABL P210 mutation detection mixed solution which comprises a BCR-ABL P210 mRNA (messenger Ribonucleic Acid) primer and probe combination and a primer and probe combination of an endogenous reference gene GUSB (Glutathione Universal Serial Bus) mRNA (messenger Ribonucleic Acid); and positive control, negative control and blank control. On a MicroDrop-100 digital PCR platform, RNA extracted from a peripheral blood or bone marrow sample is directly used as a template through a one-step method, additional experiments for reverse transcription of RNA into cDNA are not needed, an absolute quantitative result can be obtained without concentration of RNA and detection of target gene copy number in the RNA sample, a standard curve does not need to be established, the single-hole detection sensitivity can reach 0.001%, and therefore, the method has the advantages of simple and efficient detection process, absolute quantification, high specificity, high accuracy, high sensitivity and the like.

The invention relates to an acute myeloid leukemia miRNA and transcription factor model and a construction method and application thereof. The construction method includes: acquiring differential expression miRNA and different expression transcription factors of marrow samples of acute myeloid leukemia patients and a healthy contrast group, constructing a miRNA-transcription factor regulatory network model to obtain core miRNA and core transcription factors, and the like. The constructed miRNA and transcription factor model can be used for construction of diagnosis probes, chips or reagents, equipment and the like to provide intermediate result information or reference information for diagnosis of the acute myeloid leukemia patients. By the acute myeloid leukemia miRNA and transcription factor model, microRNA mediated network regulation contents are enriched, and an action mechanism of a microRNA and transcription factor mediated regulation network in AML (acute myeloid leukemia) is revealed. Research results lay the foundation for development of anti-leukemia medicines or biological products, and high application value is achieved.

The invention discloses a closed blood and bone marrow pushing device. The device comprises an operation chamber and guide rails, the operation chamber is an open box body, vertical walls in the leftside and the right side of the open box body are kept parallel, the symmetrical guide rails are arranged on the inner side faces of the vertical walls on the left side and the right side, and a support capable of clamping a sample push piece to keep a fixed angle and sliding along the guide rails is arranged between the guide rails. The blood and bone marrow smear pushing device has the advantagesthat blood and bone marrow smears are prepared in the closed operation chamber, air and operators can be prevented from pollution caused by blood and bone marrow sample aerosol, the prepared blood and bone marrow smears are uniform in thickness, later observation and analysis are better facilitated, and non-laboratory doctors and non-hematology doctors can operate the device easily. The device has the characteristics of improving the preparation quality of blood and bone marrow smears and improving the clinical operation efficiency.

The invention discloses a hematology bone marrow puncture extracting device. The device comprises an outer tube body and a base, the outer tube body is internally and fixedly connected with an inner tube body, a first piston is slidably connected between the inner surface of the outer tube body and the outer surface of the inner tube body, the top of the first piston is fixedly connected with a pushing tube, the pushing sleeves the inner tube body, the top of the pushing tube extends to the exterior of the outer tube body, the top of the pushing tube is fixedly connected with a first pushing plate, and the hematology bone marrow puncture extracting device relates to the technical field of medical instruments. The hematology bone marrow puncture extracting device has the advantages that theouter tube body and the inner tube body are cooperatively used together with an inner needle head and an outer needle head, the outer tube body is used for storing anaesthetic, the inner tube body isused for storing bone marrow samples, so that the extracted bone marrow does not contain the anaesthetic, the quality of bone marrow is not influenced, a first piston and a second piston can be pushed to slide by the pushing tube and a crossed pushing rod respectively to be used for anaesthetic injection and bone marrow extraction, the pushing tube and the crossed pushing rod do not interfere with each other, and the use is convenient.

The invention relates to the field of leukaemia drug resistance and discloses application of an ALC1 inhibitor to preparation of a leukaemia drug resistance reversing agent and application of an ALC1 gene to preparation of a drug-resistant leukaemia diagnosing reagent. The expression of the ALC1 gene in a peripheral blood sample or a bone marrow sample of a patient is detected; and based on a characteristic that the high expression of the gene is related to the increase of the resistance of a cell to chemotherapeutic medicines, sensitive chemotherapeutic agents can be screened. The invention further discloses an application of the ALC1 gene to preparation of the leukaemia drug resistance reversing agent. By inhibiting the expression of the ALC1 gene, the drug resistance of the cell can be reversed, the sensitivity of a leukemia cell to the medicine can be improved, and the cell inhibiting effects and the apoptosis promoting effects of various chemotherapeutic medicines can be improved, so that the ALC1 inhibitor can be applied to the preparation of acute and chronic leukaemia multidrug resistance reversing agents and a new method for treating the drug-resistant leukaemia is provided.

The method of the present invention can rapidly identify with expected accuracy those that are likely to respond to farnesyl transferase inhibitors and etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan AML patients, including elderly AML patients, who respond to a combination of one or more of , trastuzumab, and cisplatin. In one embodiment, the improvement includes using whole blood instead of the usual bone marrow sample, making the test more accurate, faster, less intrusive, less expensive and less painful. The method includes evaluating the expression ratio of the two genes (RASGRP1:APTX) in combination with corresponding thresholds, which provides sufficient precision for the prediction of response to combination therapy. A preferred embodiment is the combination therapy of tipifarnib (R1 15777,) combined with etoposide. Further, elderly AML patients identified as likely to respond to the combination of tipifarnib and etoposide had full recovery rates comparable to younger patients under optimal treatment conditions.